PHILADELPHIA, June 16 /PRNewswire-USNewswire/ -- The Pew Charitable Trusts today named 10 promising young scientists as Pew Latin American Fellows in the Biomedical Sciences. The rigorously competitive program provides $60,000 in salary support for postdoctoral level scientists to work with leading researchers in the United States. Upon returning to Latin America, Fellows receive an additional $35,000 to purchase essential equipment to continue their research in their home countries.
"Pew's Latin American Fellows Program is designed to further the development of outstanding scientists by providing them with excellent training in high-quality scientific laboratories in the U.S.," said Rebecca W. Rimel, President and CEO of The Pew Charitable Trusts. "We are proud to invest in Latin America's scientific future. These Fellows will help lead the global advance of research to protect and promote the health of the public."
The Latin American Fellows Program is one of The Pew Charitable Trusts' two long-standing commitments in this field, which also includes the Pew Scholars in the Biomedical Sciences, a program for America's leading early-career scientists. The Fellows program was launched in 1991 to help develop a community of highly-trained researchers who could stimulate and contribute to the growth of important biomedical research, and to foster collaboration between scientists in Latin America and the U.S.
Since 1991, Pew has invested over $14 million to fund over 175 fellows, close to 80 percent of whom have returned to their home countries. Applicants from all Central and South American countries are invited to apply to the program, and selection is made by a distinguished national advisory committee, chaired by Dr. Torsten N. Wiesel, president emeritus of Rockefeller University and a 1981 Nobel laureate in physiology or medicine.
The 2009 Pew Latin American Fellows in the Biomedical Sciences are:
- Diego Ezequiel Alvarez, Ph.D.
- Laboratory of Herve Agaisse, Ph.D.
- Yale University
- Microbial Pathogenesis
- Facundo German Pelorosso, M.D.
- Laboratory of Allan Balmain, M.D.
- University of California, San Francisco
- Cancer biology
- Ileana Slavin, Ph.D.
- Laboratory of Jeanne F. Loring, Ph.D.
- The Scripps Research Institute
- Gene expression of stem cells
- Kelly Grace Magalhaes, Ph.D.
- Laboratory of David B. Moody, M.D.
- Brigham and Women's Hospital
- Tuberculosis and the immune system
- Joao P.B. Monteiro, M.D., Ph.D.
- Laboratory of Ronald N. Germain, Ph.D.
- NIAID, National Institute of Health (NIH)
- Immune system memory
- Luis Francisco Zirnberger Batista, Ph.D.
- Laboratory of Steven Artandi, M.D., Ph.D.
- Stanford University
- Telomere complex and genetic disease
- Veronica Eisner, Ph.D.
- Laboratory of Gyorgy Hajnoczky, M.D., Ph.D.
- Thomas Jefferson University
- Mitochondria and muscular disease
- Ramon A. Jorquera, Ph.D.
- Laboratory of J. Troy Littleton, M.D., Ph.D.
- Massachusetts Institute of Technology
- Neuronal communication
- Andres Klein, Ph.D.
- Laboratory of Matthew P. Scott, Ph.D.
- Stanford University
- Niemann Pick Type C disease
- Paulina Cortes-Hernandez, M.D., Ph.D.
- Laboratory of Jodi M. Nunnari, Ph.D.
- University of California, Davis
- Mitochondrial division and cell death
For full biographies and information regarding the fellows' research subjects, please visit www.pewlatinfellows.org.
The Pew Charitable Trusts (www.pewtrusts.org) is driven by the power of knowledge to solve today's most challenging problems. Pew applies a rigorous, analytical approach to improve public policy, inform the public and stimulate civic life. We partner with a diverse range of donors, public and private organizations and concerned citizens who share our commitment to fact-based solutions and goal-driven investments to improve society.
Related biology technology :1
|SOURCE The Pew Charitable Trusts|
Copyright©2009 PR Newswire.
All rights reserved
. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial2
. Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer3
. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer4
. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting5
. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial6
. Spiral Biotech to Introduce New Autoplate Spiral Plating System at ASM General Meeting in May7
. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US8
. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer9
. PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office10
. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 200911
. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer